A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis

Furuse, Kiyoyuki; Kamimori, Takao; Kawahara, Mutsuto; Kodama, Nobuhiro; Ogawara, Mitsumasa; Atagi, Shinji; Naka, Nobuyuki; Akira, Masanori; Kubota, Keiichi

doi:10.1038/bjc.1997.108

Cited by 25 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Encouraging evidence of the efficacy and an increase in the local response rate has been obtained in studies of concurrent radiotherapy and chemotherapy with carboplatin only, 17 or combined chemotherapy with CDDP, vinorelbine, and ifosfamide, 18 or combined chemotherapy with CDDP, mitomycin C, and vindesine. 19 The intracranial response rates in these studies were 50%, 75.5%, and 56%, while the median survival times were 5.6, 9.7, and 7.6 a b…”

Section: Discussionmentioning

confidence: 98%

Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only

et al. 2005

View full text Add to dashboard Cite

We report two patients with non-small-cell lung cancer (NSCLC) with concomitant metastases to the brain only who received chemotherapy with concurrent radiotherapy for the thoracic disease and brain disease, resulting in long-term survival. One patient was a 56-year-old woman who was diagnosed as having adenocarcinoma and showed T2N1 thoracic disease; the other patient was a 57-year-old man diagnosed with squamous cell carcinoma who had T1N3 thoracic disease. Both patients demonstrated multiple metastases to the brain only. Chemotherapy, consisting of cisplatin (40 mg/m2) and docetaxel (40 mg/m2), was administered on days 1 and 8, with the drugs being given separately, and the chemotherapy was repeated every 4 weeks for up to three cycles. Whole-brain irradiation (2 Gy/day; total, 36 Gy) and thoracic irradiation (2 Gy/day; total, 60 Gy) were started on days 1 and 29, respectively. Toxicities encountered were manageable by conventional therapy. The concurrent chemoradiation therapy resulted in complete regression of the brain disease in both patients. Brain disease relapsed in the female patient, but it is being controlled by the administration of gefitinib. She has survived for 53 months since the start of treatment, without new metastatic lesions or relapse of the thoracic lesions. The male patient has survived for 37 months without new metastatic lesions or relapses. Concurrent chemoradiotherapy in which radiotherapy is applied to both the brain and thoracic lesions may be effective for patients with NSCLC with metastases to the brain only.

show abstract

Section: Discussionmentioning

confidence: 98%

Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only

et al. 2005

View full text Add to dashboard Cite

show abstract

“…For many years, WBRT had been standard treatment for BM from NSCLC with OS ranging from 3 to 6 months. The addition of systematic chemotherapy to WBRT was shown to improve outcome for patients with BM from lung cancer, and the median OS was 7.6-8 months (Furuse et al, 1997;Quantin et al, 1999;Moscetti et al, 2007). Gefitinib, as a novel target therapeutic drug, has been commonly used for treating NSCLC in recent years.…”

Section: Discussionmentioning

confidence: 99%

“…Chemotherapy leads to a median survival of 3-6 months for patients with BM from NSCLC. Few pilot studies reported that patients with BM from NSCLC treated with chemotherapy concurrently with WBRT had a median OS of 7.6-8 months (Furuse et al, 1997;Quantin et al, 1999;Moscetti et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Yin¹,

Zhang²,

Liao³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Gefitinib, a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), is used both as a single drug and concurrently with whole brain radiotherapy (WBRT) the standard treatment for brain metastases (BM), and is reported to be effective in a few small studies of patients with BM from non-small-cell lung cancer (NSCLC). However, no study has compared the two treatment modalities.

show abstract

“…The median survival time was 382 days and the 1-year survival rate was 56.1%, which was considered satisfactory. Furuse et al [11]reported that concurrent WBRT and chemotherapy with cisplatin, vindesine, and mitomycin produced high rates (75.8%) of brain metastasis control and resulted in a median survival of 9.7 months. The response rate in primary lesions was 18%.…”

Section: Discussionmentioning

confidence: 99%

Combination Chemotherapy of Cisplatin, Ifosfamide, and Irinotecan with rhG-CSF Support in Patients with Brain Metastases from Non-Small Cell Lung Cancer

Fujita

Fukuoka²,

Takabatake³

et al. 2000

Oncology

View full text Add to dashboard Cite

Background: Brain metastases develop frequently in patients with non-small cell lung cancer (NSCLC), and the prognosis for these patients is very poor. We evaluated the role of chemotherapy for patients with brain metastases from NSCLC. Methods: We analyzed 30 patients who were discovered to have brain metastases during the diagnosis of 121 patients enrolled in three consecutive clinical trials on advanced NSCLC assessing combination chemotherapy of cisplatin, ifosfamide and irinotecan with rhG-CSF support. Response in the brain lesions was evaluated by contrast-enhanced MRI scans after at least two courses. Results: Fourteen patients achieved a partial response (PR) but there was no change (NC) in 13 patients and progressive disease (PD) in 1. Among patients with extracranial lesions, 18 had a PR and 11 had NC. The response rate in brain metastases was 50.0%, and that in extracranial primary and metastatic lesions was 62.1%. The median duration of response for intra- and extracranial lesions was 140 and 147 days, respectively. After completing chemotherapy, Gamma Knife radiosurgery was performed on 2 patients in remission and 8 patients at disease progression. The median survival time and 1-year survival rate were 382 days and 56.1%, respectively. Conclusions: Both the response rate and survival data in this retrospective study suggest a high degree of activity of this combination chemotherapy in patients with brain metastases from NSCLC.

show abstract

A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis

Cited by 25 publications

References 26 publications

Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only

Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Combination Chemotherapy of Cisplatin, Ifosfamide, and Irinotecan with rhG-CSF Support in Patients with Brain Metastases from Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About